Dexcom in talks to acquire Insulet

 Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD).

Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg’s sources preferred to remain anonymous because the information is private and both companies declined to offer comment, the news outlet said.

No potential financial figures related to any acquisition discussions were revealed in the report.

San Diego-based Dexcom, a leader in continuous glucose monitoring (CGM) technology, and Insulet, an Acton, Massachusetts-based automated insulin delivery technology maker, are not new to one another. The two companies partnered in early 2020 to use Dexcom’s CGM with Insulet’s wearable pump and have since worked together on next-generation technologies, as Insulet’s recently FDA-cleared Omnipod 5 automated insulin delivery system uses Dexcom’s G6 CGM.

Officials from both companies have previously said that once Dexcom’s next-generation G7 CGM receives FDA approval — which could come as soon as next month with current expectations of a regulatory nod after the American Diabetes Association Scientific Sessions —  work will be done to integrate it into the Omnipod 5 platform.

The news of a potential acquisition comes at an interesting time as Insulet announced earlier this month that CEO Shacey Petrovic was stepping down due to personal reasons. She will be succeeded by ResMed President of Sleep and Respiratory Care Jim Hollingshead, beginning June 1.

https://www.drugdeliverybusiness.com/dexcom-in-talks-to-acquire-insulet/